CARsgen Therapeutics is a leading biopharmaceutical company focusing on cancer immunotherapy with expertise on CAR-T therapy. As one of industry leaders in target discovery, antibody discovery and cancer immunotherapy, the company has launched several First-in-Class CAR-T clinical trials to treat the relapsed/refractory tumors, including CAR-GPC3-T trial for hepatocellular carcinoma and squamous lung cancer, CAR-EGFR/ EGFRvIII-T trial for glioblastoma multiforme (GBM), and CAR-Claudin18.2-T trial for gastric and pancreatic cancer. CARsgen also has ongoing clinical programs of the humanized CAR-CD19-T trial for leukemia and the fully human CAR-BCMA-T trial for multiple myeloma globally.
CARsgen currently has a leading pipeline of over 10 CAR-T candidates covering most hematologic and solid cancer. By September 2020, CARsgen has received 5 Investigational New Drug Clearance for CAR-GPC3-T, CAR-Claudin18.2-T, CAR-CD19-T, CAR-BCMA-T and Humanized Claudin18.2 Monoclonal Antibody from the National Medical Products Administration. Meanwhile, CARsgen has received Investigational New Drug Clearance for CAR-BCMA-T from the U.S. FDA and Health Canada and CAR-Claudin18.2-T from the U.S. FDA. In addition, CARsgen has over 150 patents including next generation CAR-T technologies improvement.